Vertex Pharmaceuticals has halted the development of its non-opioid painkiller, creating uncertainty but also a potential opening for competitors. This theme focuses on other pharmaceutical companies that could capture market share as they advance their own non-opioid treatments.
Published on August 5
With Vertex stepping back, these companies could be the first to crack the code on effective non-opioid painkillers. The company that succeeds could dominate a massive market worth billions.
The opioid epidemic has created urgent demand for safer pain management alternatives. These biotech firms are racing to develop treatments that could transform healthcare and save lives.
Clinical trial results in this sector can send stock prices soaring or plummeting overnight. Each company represents a calculated bet on breakthrough medical innovation with potentially massive rewards.
Vertex Pharmaceuticals' recent halt of its non-opioid painkiller development has created a significant opportunity in the pain management sector. This setback highlights the immense challenge of developing effective alternatives to traditional opioids, but also opens the door for competitors with promising treatments in their pipelines.
These are high-risk, high-reward biotech investments where clinical trial outcomes can dramatically impact valuations. The companies operate in a sector with enormous potential rewards for successful non-opioid pain treatments, but significant risks as drug development can fail at any stage.
Each company has been carefully selected for their active involvement in developing novel analgesic treatments. With one major competitor stepping back, these firms are positioned to potentially capture market share in the race to deliver the next generation of pain relief solutions.
Market capitalisation breakdown for the 'Beyond Opioids: The Race For New Painkillers' basket.
NRXP: $76.30M
COLL: $1.11B
PCRX: $989.42M
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
+4
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
BHP Group recently posted a massive earnings beat driven by record copper profitability, allowing the miner to raise its dividend to a four-year high. This performance highlights a structural shift toward electrification metals, creating opportunities for industrial equipment suppliers and competing copper producers.
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+191.27%
On average, analysts expect assets in this group to grow 191.27% over the next year.
11 of 14 assets in this group are rated Buy by professional analysts.
